Improving the emergency department management of Post-Chemotherapy sepsis in haematological malignancy patients

Hong Kong Medical Journal

Volumn 21, Issue 1, 2015, Pages 10-15

  Ko, H F ^a   Tsui, S S ^a   Tse, Johnson W K ^a   Kwong, W Y ^a   Chan, O Y ^b   Wong, Gordon C K ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; ARTICLE; BACTEREMIA; CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; EMERGENCY WARD; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HEMATOLOGIC MALIGNANCY; HUMAN; LENGTH OF STAY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOUTH TEMPERATURE; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NEUTROPHIL COUNT; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; SELF REPORT; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS MITIS; TREATMENT DURATION; TREATMENT PLANNING; CHEMICALLY INDUCED; CLINICAL PROTOCOL; COMPLICATION; EMERGENCY HEALTH SERVICE; EVALUATION STUDY; HEMATOLOGIC NEOPLASMS; HONG KONG; MIDDLE AGED; PRACTICE GUIDELINE; STANDARDS; STATISTICS AND NUMERICAL DATA; TIME TO TREATMENT; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CLINICAL PROTOCOLS; EMERGENCY SERVICE, HOSPITAL; FEMALE; GUIDELINE ADHERENCE; HEMATOLOGIC NEOPLASMS; HONG KONG; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEPSIS; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 84922832828     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: 10.12809/hkmj144280     Document Type: Article

References (19)

1. Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 2004;39 Suppl 1:S32-7.
2. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
3. Herbst C, Naumann F, Kruse EB, et al. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst Rev 2009;(1):CD007107.
4. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56-93.
5. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
6. Bate J, Gibson F, Johnson E, et al. Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (NICE Clinical Guideline CG151). Arch Dis Child Educ Pract Ed 2013;98:73-5.
7. Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013;31:794-810.
8. Clarke RT, Warnick J, Stretton K, Littlewood TJ. Improving the immediate management of neutropenic sepsis in the UK: lessons from a national audit. Br J Haematol 2011;153:773-9.
9. Andre S, Taboulet P, Elie C, et al. Febrile neutropenia in French emergency departments: results of a prospective multicentre survey. Crit Care 2010;14:R68.
10. Hui EP, Leung LK, Poon TC, et al. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer 2011;19:1625-35.
11. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
12. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18:3038-51.
13. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96.
14. Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010;38:1045-53.
15. Sammut SJ, Mazhar D. Management of febrile neutropenia in an acute oncology service. QJM 2012;105:327-36.
16. Lim C, Bawden J, Wing A, et al. Febrile neutropenia in EDs: the role of an electronic clinical practice guideline. Am J Emerg Med 2012;30:5-11, 11.e1-5.
17. Nirenberg A, Mulhearn L, Lin S, Larson E. Emergency department waiting times for patients with cancer with febrile neutropenia: a pilot study. Oncol Nurs Forum 2004;31:711-5.
18. Hitti EA, Lewin JJ 3rd, Lopez J, et al. Improving door-toantibiotic time in severely septic emergency department patients. J Emerg Med 2012;42:462-9.
19. Legrand M, Max A, Peigne V, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 2012;40:43-9.